IP Library › Granted Patent US 7,887,806
Granted Patent B2
US 7,887,806 · App. 12/834,728 · Granted Feb 15, 2011

Mammalian receptor proteins DCRS5; method of treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,887,806
App. No.
12/834,728
Granted
Feb 15, 2011
Kind
B2
Abstract

Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Claims (14)

1. A method of treating a human subject experiencing rheumatoid arthritis comprising administering an effective amount of an antagonist antibody that specifically binds to DCRS5 (SEQ ID NO: 2), or an antigen binding fragment thereof.

2. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a polyclonal antibody.

3. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a monoclonal antibody.

4. The method of claim 1 , wherein the antibody or an antigen binding fragment thereof comprises an Fab, Fv, or F(ab′)2 antibody fragment of a monoclonal antibody.

5. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a humanized antibody.

6. The method of claim 1 , wherein the antibody or an antigen binding fragment thereof comprises an Fab, Fv, or F(ab′)2 antibody fragment of a humanized antibody.

7. The method of claim 1 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′)2 antibody fragment.

8. A method of treating a human subject experiencing rheumatoid arthritis comprising administering an effective amount of an antagonist antibody that specifically binds to a polypeptide comprising residues 1-606 of SEQ ID NO: 2, or an antigen binding fragment thereof.

9. The method of claim 8 , wherein the antibody or antigen binding fragment thereof comprises a polyclonal antibody.

10. The method of claim 8 , wherein the antibody or antigen binding fragment thereof comprises a monoclonal antibody.

11. The method of claim 8 , wherein the antibody or an antigen binding fragment thereof comprises a humanized antibody.

12. The method of claim 8 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′)2 antibody fragment.

13. The method of claim 8 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′)2 antibody fragment of a monoclonal antibody.

14. The method of claim 8 , wherein the antibody or antigen binding fragment thereof comprises an Fab, Fv, or F(ab′)2 antibody fragment of a humanized antibody.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →